NLRP3 and pulmonary fibrosis: The data suggest that by inhibiting excessive inflammation through the suppression of the NLRP3 inflammasome pathway, which is responsible for the release of proinflammatory cytokines, it might be possible to mitigate lung tissue damage and hinder disease progression, including the development of conditions like lung fibrosis.